His role includes shaping the clinical evidence strategy and product design for Medtronic’s diabetes technology. The company also expects him to strengthen its presence in Central Europe, the Middle East and Africa.
Petrovski brings more than 20 years of experience as an endocrinologist and diabetologist to Medtronic. He served as a professor in the University Clinic of Endocrinology/Medical Faculty in Skopje, Macedonia, and Weill Cornell Medicine, Qatar. Petrovski has published more than 100 papers in peer-reviewed journals, written or co-written eight books on type 1 diabetes and has been vocal on the use of technologies like advanced hybrid closed loop therapy (AHCL) and smart multiple daily injection (MDI) systems.
Most recently, Petrovski served as senior attending physician at Sidra Medicine, Weill Cornell University in Doha, Qatar. There, he conducted research, including clinical studies for Medtronic. Last year, he presented a study highlighting Medtronic’s MiniMed 780G’s performance in adolescents.
At that time, Petrovski said meal management with the MiniMed 780G system helped users maintain glycemic targets while providing forgiveness for inexact carb counts. He saw “more runway for simplification of diabetes management” with the “promising” system. Since then, MiniMed 780G was actually recognized as a “World-Changing Idea” by Fast Company.
“Medtronic shares Dr. Petrovski’s passion and commitment to helping people with diabetes across the globe and we are privileged to welcome such a renowned expert to our team. We look forward to his contribution to our innovation and evidence strategy” said Dr. Robert Vigersky, chief medical officer for Medtronic Diabetes.
